RYAM's Strategic Review Slips, and the Script Quietly Gets Rewritten
A 50% paperboard tariff idles Témiscaming, drives a $221 million writedown and pushes the sale process to Q1 2027 — while the CEO who swore off asset closures is already gone
RYAM · Earnings Call · 2026-11-04
The Delay Nobody Scheduled
On the numbers, RYAM's third quarter was the best operating quarter it has strung together in years. Adjusted EBITDA rose to $52 million from $40 million in the second quarter, High Purity Cellulose contributed $73 million at a 23% margin, and the price premium that anchors the whole equity story — specialty cellulose at $2,227 per metric ton versus $825 for commodity grade, a 170% spread — is intact. Dan Krawczyk, four months into the job, spent most of his prepared remarks explaining how good that franchise is.
And then he buried the quarter. “The U.S. tariff on Canadian paperboard and resulting economic idling of Témiscaming have caused a delay in the review timeline.” — Dan Krawczyk, President and Chief Executive Officer · 2026-11-04 The strategic review, launched in April 2026 with Morgan Stanley and repeatedly guided to a fourth-quarter conclusion, is now targeted for Q1 2027. The quarter carried a $229 million loss from continuing operations, including $221 million of non-cash impairments primarily related to Témiscaming — the site economically idled on October 3 after the 50% U.S. tariff on Canadian paperboard made production uneconomic.
That is the shape of the whole report: an improving operating business whose equity story is hostage to a trade policy decision and a sale process that keeps moving to the right.
We expect to conclude the review and communicate a clear path during the fourth quarter.
That was Krawczyk in August. Three months later the same manager, same board mandate, same interested parties — a different quarter.
Four Voices in Four Quarters, Three Different Answers
The most telling thing about this call is not in the numbers. It is who is no longer saying what. In November 2025, De Lyle Bloomquist was gating a sale of the paperboard and high-yield pulp assets on USMCA renewal and a return to positive EBITDA. By March 2026, Scott Sutton had reversed the framing entirely: “we are not selling any business, and we are not closing any assets.” — Scott Sutton, President and CEO · 2026-03-04 By May 2026 Marcus Moeltner was speaking as CEO. By August, Krawczyk had the seat.
Now the pendulum has swung back past where it started. Asked whether the answer is more specialty volume or a smaller system, Krawczyk was unusually direct: “Not all assets fit that strategy. There are things that are not part of being a CS organization that we need to address as a company.” — Dan Krawczyk, President and Chief Executive Officer · 2026-11-04 That is a CEO pre-announcing a footprint decision he will not name — "We have not announced the strategic facility action, and I wouldn't speculate on one at this point" — while the site that everyone can see has already been idled and written down.
He also let slip a fact the press release does not contain: “we have had a management team raise their interest in a potential management buyout.” — Dan Krawczyk, President and Chief Executive Officer · 2026-11-04 A management buyout bid outstanding against a board running a strategic review, with the review slipping, is not a rounding error in the story.
The Mix Math Is Real. The Vocabulary Is Not New.
To be fair to management, the operating diagnosis is coherent and the data supports it. CS franchise economics are being buried by commodity losses inside HPC — the segment earned $73 million while the consolidated company earned $52 million, with corporate costs and a negative-$9 million paperboard result absorbing the difference. Management's answer is a deliberate production mix shift, allocating more of the same assets to specialty grades and less to commodity exposure — "reducing commodity exposure is not a marginal adjustment. It is a fundamental shift," as Krawczyk put it.
But note how long this has been the script. production mix language and the CS-versus-commodity framing have run through the company's keyword history for several quarters, under a prior CEO who called it "value over volume" and then a "NASCAR leaderboard" strategy. What is genuinely new is not the strategy — it is the admission that asset base reduction is the tool. The company's own keyword tape shows economic idling as a fresh, high-momentum theme this quarter precisely because it had never been the answer before.
What Fell Out of the Deck
The louder signal is subtraction. A quarter ago, RYAM's growth narrative had three legs beyond specialty cellulose: nitrocellulose for U.S. defense and energetics, the freezer-board and oil-and-grease board product launches at Témiscaming, and the Altamaha Green Energy project, which Bloomquist once valued at roughly "a $650 million potential impact to our ROI." On this call, nitrocellulose does not appear once. The new paperboard products are gone with the idling that killed them. And AGE — the project that was going to be a utility-like annuity — is reduced to a single clause: "Construction is also underway on the Altamaha Green Energy, or AGE, project at Jesup."
That is a company narrowing its story to one asset class and one process outcome.
The contrast with the broader market is sharp. Tariff refunds are among the hottest themes in the global keyword tape right now — Tariff Refund ranked first market-wide in 2026Q2, with IEEPA refund and net tariff refunds threading through chemical, packaging and medical-device calls as a source of upside. RYAM sits on the opposite side of that trade: its tariff line is a cost, $2 million in the quarter, with the countervailing benefit from Brazilian and Norwegian anti-dumping duties (final rates of 9.37% CVD plus 6.4% AD on Brazil, 6.51% on Norway) still awaiting a mid-November injury determination that Krawczyk pointedly refused to lean on: "they come and go."
Cash, and the Fine Print on the Promise
The balance sheet is where the delay actually bites. Liquidity was $143 million at quarter-end — $61 million of cash plus $66 million of revolver availability — against an effective net cash position of negative $688 million. Year-to-date adjusted free cash flow was positive $2 million, a genuine turn from negative $8 million at the half. But Témiscaming now carries $2–3 million per month of idle cost, which means the fourth quarter starts roughly $6–9 million in the hole before any working capital help.
So watch the language. The full-year commitment to positive free cash flow survives verbatim from March — "Achieving that objective requires disciplined working capital management, capital spending, and cost control, and remains subject to tariff-related cash impacts and Témiscaming's carrying costs." The promise is unbroken; the conditions attached to it have quietly eaten most of the promise.
This is a company that has spent a decade shrinking: revenue of $376 million in the June quarter, a 6.1% gross margin, and an equity that has returned -80% since 2014 and sits 26% below its August peak. The third quarter proves the specialty franchise can earn. It does not prove the company can hold a timeline, a footprint, or a promise long enough for the market to pay for it.
Expect the November injury determination and the Q1 review target to be the only two catalysts that matter — and expect the market to discount both until one of them actually lands.